Results 321 to 330 of about 355,709 (346)
Some of the next articles are maybe not open access.
Durvalumab Promising for NSCLC
Cancer Discovery, 2017Abstract The PD-L1 inhibitor durvalumab increases progression-free survival and objective response rate in patients with inoperable and locally advanced stage III non–small cell lung cancer, according to interim results of a phase III trial. The benefit was great enough that the drug could become the standard of care in the United States
openaire +2 more sources
Erhaltungstherapie beim NSCLC [PDF]
Im Focus Onkologie, 2013 Es mehren sich Hinweise auf den Nutzen einer Erhaltungstherapie bei manchen Patienten mit nichtkleinzelligem Bronchialkarzinom (NSCLC). In zwei aktuellen Studien wurden ein Antimetabolit und ein Antikorper uberpruft.
openaire +1 more source
BCL3 and NSCLC: Are they related?
Journal of Clinical Oncology, 2013e18507 Background: NFkB pathways have become objects of detailed research in the last years, although, little is known of the possible role of BCL3 in lung carcinogenesis. The aim of this study was to define the relation of the BCL3 single nucleotide polymorphism rs8100239 with NSCLC and its association with BCL3 protein expression.
Chrisoula D. Scopa +8 more
openaire +2 more sources
At the crossroads of immunotherapy for oncogene-addicted subsets of NSCLC
Nature Reviews Clinical Oncology, 2023I. Otano +3 more
semanticscholar +1 more source
2019
Non-small-cell lung cancer (NSCLC) continues to be the leading cause of mortality related to lung cancer. Substantial advances have been made in the ability to identify oncogenic driver mutations that lead to the molecular cause in lung cancer. These new developments have led to an era of individualized medicine in NSCLC. BRAF in NSCLC is considered an
openaire +2 more sources
Non-small-cell lung cancer (NSCLC) continues to be the leading cause of mortality related to lung cancer. Substantial advances have been made in the ability to identify oncogenic driver mutations that lead to the molecular cause in lung cancer. These new developments have led to an era of individualized medicine in NSCLC. BRAF in NSCLC is considered an
openaire +2 more sources
Aumolertinib is effective in NSCLC [PDF]
Nature Reviews Clinical Oncology, 2021 openaire +2 more sources
Radiotherapy and hyperthermia for NSCLC
Journal of Clinical Oncology, 20057289 Background: Up to now, NSCLC with tumor(T) larger in lungs treated with irradation(RT) has poorly loco-regional control limited by tolerance dose of normal tissues. The aim of this study is to observe the toxicity, tolerance and efficacy of RT combined with hyperthemia(HT) for NSCLC with T in diameter >= 5cm. Methods: Patients(pts) satisfied NSCLC,
J. X. Liao +3 more
openaire +2 more sources
Integration of chemotherapy in early NSCLC
Lung Cancer, 2002Over 1 300 000 lung cancer deaths have been estimated in the year 2000 [1]. Such enormous fatality rate reflects the limited chance of cure, with a dismal overall 5-year survival of approximately 14% in the United States and only 10% in Europe [2]. Surgical excision is still the most effective way to achieve local control and permanent cure, but is ...
openaire +3 more sources
Selecting the optimal immunotherapy regimen in driver-negative metastatic NSCLC
Nature Reviews Clinical Oncology, 2021M. Grant, R. Herbst, S. Goldberg
semanticscholar +1 more source